Ovid Therapeutics Inc (OVID) Expected to Announce Earnings of -$0.42 Per Share

Equities research analysts predict that Ovid Therapeutics Inc (NASDAQ:OVID) will post ($0.42) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Ovid Therapeutics’ earnings. The business is expected to issue its next quarterly earnings report on Thursday, February 8th.

On average, analysts expect that Ovid Therapeutics will report full year earnings of ($4.08) per share for the current fiscal year, with EPS estimates ranging from ($4.85) to ($3.31). For the next financial year, analysts anticipate that the company will report earnings of ($2.22) per share, with EPS estimates ranging from ($2.25) to ($2.18). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Ovid Therapeutics.

Ovid Therapeutics (NASDAQ:OVID) last issued its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.16.

Several brokerages have recently weighed in on OVID. Zacks Investment Research upgraded Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Friday, January 12th. ValuEngine upgraded Ovid Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $19.33.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC purchased a new position in shares of Ovid Therapeutics in the second quarter valued at $18,254,000. Jennison Associates LLC grew its position in Ovid Therapeutics by 2.7% during the third quarter. Jennison Associates LLC now owns 667,466 shares of the company’s stock worth $5,858,000 after buying an additional 17,392 shares in the last quarter. Tekla Capital Management LLC purchased a new position in Ovid Therapeutics during the second quarter worth about $5,229,000. Redmile Group LLC purchased a new position in Ovid Therapeutics during the second quarter worth about $4,237,000. Finally, Ameriprise Financial Inc. purchased a new position in Ovid Therapeutics during the second quarter worth about $3,761,000. Institutional investors own 29.36% of the company’s stock.

Shares of Ovid Therapeutics (NASDAQ OVID) traded up $0.28 during midday trading on Friday, hitting $9.18. The stock had a trading volume of 93,201 shares, compared to its average volume of 50,672. Ovid Therapeutics has a one year low of $5.28 and a one year high of $15.93.

COPYRIGHT VIOLATION WARNING: This report was first reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/20/ovid-therapeutics-inc-ovid-expected-to-announce-earnings-of-0-42-per-share.html.

About Ovid Therapeutics

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Get a free copy of the Zacks research report on Ovid Therapeutics (OVID)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply